ISE:GVR
ISE:GVRConsumer Durables

Glenveagh Properties (ISE:GVR) Valuation After New Share Buyback And 2,000 Unit Output Guidance

Glenveagh Properties (ISE:GVR) has put two clear signals on the table: a new share buyback of up to €25 million and guidance to scale homebuilding output to about 2,000 units by 2027. See our latest analysis for Glenveagh Properties. Those capital return and growth plans come after a solid stretch of gains, with the share price at €2.01 and a 90 day share price return of 10.93%. The 1 year total shareholder return sits at 30.52% and the 5 year total shareholder return is 136.47%, suggesting...
ISE:RYA
ISE:RYAAirlines

Ryanair Holdings (ISE:RYA) Valuation Check After Recent Share Price Pullback

What Ryanair’s Recent Share Performance Tells You Ryanair Holdings (ISE:RYA) has been on investors’ radar after a recent pullback, with the stock showing a 1 day return of around a 1% decline and a 5% decline over the past week. Over the past month, Ryanair has recorded roughly a 4% decline, while the past 3 months show a gain of about 12%. Year to date, the stock is down around 5%, yet the 1 year total return sits near 58%. Against this share performance backdrop, Ryanair’s latest reported...
ISE:IRES
ISE:IRESResidential REITs

European Small Caps With Insider Action Highlighting Undervalued Opportunities

As the pan-European STOXX Europe 600 Index reaches new heights, buoyed by an improving economic backdrop and marking its strongest yearly performance since 2021, investors are increasingly focusing on small-cap opportunities within this dynamic market landscape. In such a thriving environment, identifying stocks with strong fundamentals and insider activity can highlight potential undervalued opportunities in the European small-cap sector.
ISE:UPR
ISE:UPRHealthcare

Is Uniphar’s Rare-Disease Logistics Expansion with Zevra Reshaping the Investment Case for Uniphar (ISE:UPR)?

Zevra Therapeutics announced that it has entered into an exclusive expanded access distribution agreement with Ireland-based Uniphar, enabling Niemann-Pick Disease Type C patients in select territories outside Europe to obtain reimbursed named-patient supply of MIPLYFFA, the only approved therapy that targets the underlying pathology of this ultra-rare condition. The deal strengthens Uniphar’s position as a specialist partner for complex rare-disease logistics, highlighting its capabilities...
ISE:RYA
ISE:RYAAirlines

Should Ryanair’s Robust December Traffic and Load Factors Shape a Rethink for (ISE:RYA) Investors?

Ryanair Holdings plc has reported its December 2025 traffic results, with 14.5 million guests for the month and 206.5 million year to date, while maintaining load factors of 92% and 94% respectively, broadly in line with the prior year. The combination of rising guest numbers and consistently high load factors points to sustained demand for Ryanair’s network and capacity deployment. We will now examine how this continued growth in guest numbers shapes Ryanair’s investment narrative and...
ISE:PTSB
ISE:PTSBBanks

How Is Permanent TSB's (ISE:PTSB) Recent Lending Activity Shaping Its Earnings Prospects?

Permanent TSB Group Holdings plc recently released its Q3 2025 sales and trading statement during a scheduled call on October 30, 2025, offering investors updated insights into its operational performance for the quarter. This quarterly update provided stakeholders with key details about recent lending activity, cost management progress, and broader trends influencing the bank's outlook in Ireland's evolving financial landscape. We'll examine how the latest quarterly trading statement update...